Anti-CD5L antibody and uses thereof
The invention relates to a CD5L-binding agent or a pharmaceutical composition thereof for use in the treatment of cancer by inhibiting macrophage M2 activation or promoting lymphocyte activation.
1. A method of inhibiting the immunosuppressive M2 phenotype in macrophages in a mammal in need thereof, the method comprising: administering to the mammal a pharmaceutical composition comprising a therapeutically effective amount of a CD5L-binding agent capable of inhibiting the immunosuppressive M2 phenotype in macrophages, together with one or more pharmaceutically acceptable carriers or excipients;
wherein the CD5L-binding agent is an anti-CD5L monoclonal antibody capable of inhibiting the immunosuppressive M2 phenotype in macrophages, wherein said anti-CD5L monoclonal antibody comprises:
a. a VH sequence comprising, in the following specified order, a CDR1 of sequence consisting of SEQ ID NO: 3, a CDR2 of sequence consisting of SEQ ID NO: 4, and a CDR3 of sequence consisting of SEQ ID NO: 1; and
b. a VL sequence comprising, in the following specified order, a CDR1 of sequence consisting of SEQ ID NO: 5, a CDR2 of sequence consisting of SEQ ID NO: 6, and a CDR3 of sequence consisting of SEQ ID NO: 2.
2. The method of claim 1 , wherein the method produces a pro-inflammatory response in the mammal.
3. The method of claim 1 , wherein the method is an immunotherapy method for treatment of cancer.
4. The method of claim 3 , wherein the cancer is selected from the group consisting of: papillomas, adenomas, lipomas, osteomas, myomas, angiomas, nevi, mature teratomas, carcinomas, sarcomas, immature teratomas, melanoma, myeloma, leukemia, Hodgkin's lymphoma, basalioma, spinalioma, breast cancer, ovarian cancer, uterine cancer, lung cancer, bronchial cancer, prostate cancer, colon cancer, pancreatic cancer, kidney cancer, esophageal cancer, hepatocellular carcinoma (HCC), and head and neck cancer.
5. A kit comprising:
(a) a CD5L-binding agent, wherein the CD5L-binding agent is an anti-CD5L monoclonal antibody capable of inhibiting the immunosuppressive M2 phenotype in macrophages, wherein said anti-CD5L monoclonal antibody comprises:
a. the VH sequence comprises, in the following specified order, a CDR1 of sequence consisting of SEQ ID NO: 3, a CDR2 of sequence consisting of SEQ ID NO: 4, and a CDR3 of sequence consisting of SEQ ID NO: 1; and
b. the VL sequence comprises, in the following specified order, a CDR1 of sequence consisting of SEQ ID NO: 5, a CDR2 of sequence consisting of SEQ ID NO: 6, and a CDR3 of sequence consisting of SEQ ID NO: 2; and
(b) instructions for administering the CD5L binding agent to a mammal to induce a pro-inflammatory response and inhibit M2 activation in the mammal.
6. The kit of claim 5 , wherein the administering is for cancer immunotherapy.
7. A method of inhibiting the immunosuppressive M2 phenotype in macrophages in a mammal in need thereof, the method comprising: administering to the mammal a pharmaceutical composition comprising a therapeutically effective amount of a CD5L-binding agent capable of inhibiting the immunosuppressive M2 phenotype in macrophages, together with one or more pharmaceutically acceptable carriers or excipients;
wherein the CD5L-binding agent is an anti-CD5L monoclonal antibody capable of inhibiting the immunosuppressive M2 phenotype in macrophages;
wherein said anti-CD5L monoclonal antibody comprises:
a. a heavy chain consisting of SEQ ID NO: 9; and
b. a light chain consisting of SEQ ID NO: 10.
8. The method of claim 7 , wherein the method produces a pro-inflammatory response in the mammal.
9. The method of claim 7 , wherein the method is an immunotherapy method for treatment of cancer.
10. The method of claim 9 , wherein the cancer is selected from the group consisting of: papillomas, adenomas, lipomas, osteomas, myomas, angiomas, nevi, mature teratomas, carcinomas, sarcomas, immature teratomas, melanoma, myeloma, leukemia, Hodgkin's lymphoma, basalioma, spinalioma, breast cancer, ovarian cancer, uterine cancer, lung cancer, bronchial cancer, prostate cancer, colon cancer, pancreatic cancer, kidney cancer, esophageal cancer, hepatocellular carcinoma (HCC), and head and neck cancer.
11. A kit comprising:
(a) a CD5L-binding agent wherein the CD5L-binding agent is an anti-CD5L monoclonal antibody capable of inhibiting the immunosuppressive M2 phenotype in macrophages;
wherein said anti-CD5L monoclonal antibody comprises:
a. a heavy chain consisting of SEQ ID NO: 9; and
b. a light chain consisting of SEQ ID NO: 10; and
(b) instructions for administering the CD5L binding agent to a mammal to induce a pro-inflammatory response and inhibit M2 activation in the mammal.
12. The kit of claim 11 , wherein the administering is for cancer immunotherapy.